Publication | Closed Access

Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response

Immunotherapy ResponseNeuro-oncologyCancer ImmunosurveillanceImmune-checkpoint MoleculeGliomaImmunologyImmunologic MechanismImmune Checkpoint InhibitorSiglec-9 ActsCellular Immune ResponseImmunotherapyMedicineCell BiologyTumor Microenvironment